ChingLam W Wong
Overview
Explore the profile of ChingLam W Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, et al.
Clin Cancer Res
. 2017 Oct;
24(1):106-119.
PMID: 29061640
Multiple myeloma remains an incurable malignancy of plasma cells despite considerable advances in treatment. The purpose of the study was to develop novel chimeric antigen receptors (CAR) for the treatment...
2.
Urak R, Walter M, Lim L, Wong C, Budde L, Thomas S, et al.
J Immunother Cancer
. 2017 Mar;
5:26.
PMID: 28331616
Background: Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing...
3.
Wang X, Popplewell L, Wagner J, Naranjo A, Blanchard M, Mott M, et al.
Blood
. 2016 Apr;
127(24):2980-90.
PMID: 27118452
Myeloablative autologous hematopoietic stem cell transplantation (HSCT) is a mainstay of therapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma (NHL); however, relapse rates are high. In phase 1 studies designed to...
4.
Wang X, Wong C, Urak R, Taus E, Aguilar B, Chang W, et al.
Oncoimmunology
. 2016 Mar;
5(1):e1072671.
PMID: 26942092
Human CD8 effector T cells derived from CD45ROCD62L precursors enriched for central memory (T) precursors retain the capacity to engraft and reconstitute functional memory upon adoptive transfer, whereas effectors derived...
5.
Wang X, Wong C, Urak R, Mardiros A, Budde L, Chang W, et al.
Clin Cancer Res
. 2015 Apr;
21(13):2993-3002.
PMID: 25838392
Purpose: T cells engineered with chimeric antigen receptors (CAR) recognizing CD19 can induce complete remission of B-cell malignancies in clinical trials; however, in some disease settings, CAR therapy confers only...
6.
Wang X, Naranjo A, Brown C, Bautista C, Wong C, Chang W, et al.
J Immunother
. 2012 Oct;
35(9):689-701.
PMID: 23090078
A key determinant of the therapeutic potency of adoptive T-cell transfer is the extent to which infused cells can persist and expand in vivo. Ex vivo propagated virus-specific and chimeric...
7.
Wang X, Chang W, Wong C, Colcher D, Sherman M, Ostberg J, et al.
Blood
. 2011 Jun;
118(5):1255-63.
PMID: 21653320
An unmet need in cell engineering is the availability of a single transgene encoded, functionally inert, human polypeptide that can serve multiple purposes, including ex vivo cell selection, in vivo...
8.
Wang X, Berger C, Wong C, Forman S, Riddell S, Jensen M
Blood
. 2010 Dec;
117(6):1888-98.
PMID: 21123821
In clinical trials of adoptive T-cell therapy, the persistence of transferred cells correlates with therapeutic efficacy. However, properties of human T cells that enable their persistence in vivo are poorly...